Cargando…

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry

BACKGROUND: Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation care quality and clinical outcomes among pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perino, Alexander C., Shrader, Peter, Turakhia, Mintu P., Ansell, Jack E., Gersh, Bernard J., Fonarow, Gregg C., Go, Alan S., Kaiser, Daniel W., Hylek, Elaine M., Kowey, Peter R., Singer, Daniel E., Thomas, Laine, Steinberg, Benjamin A., Peterson, Eric D., Piccini, Jonathan P., Mahaffey, Kenneth W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512133/ https://www.ncbi.nlm.nih.gov/pubmed/31023126 http://dx.doi.org/10.1161/JAHA.118.011205

Ejemplares similares

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
por: Jackson, Larry R., et al.
Publicado: (2018)

Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
por: Thomas, Kevin L., et al.
Publicado: (2017)

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
por: O'Brien, Emily C., et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
por: Fudim, Marat, et al.
Publicado: (2018)

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
por: Jackson, Larry R., et al.
Publicado: (2018)

Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
por: Washam, Jeffrey B., et al.
Publicado: (2018)

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
por: Steinberg, Benjamin A., et al.
Publicado: (2018)

Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry
por: O'Brien, Emily C., et al.
Publicado: (2016)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
por: Jackson, Larry R., et al.
Publicado: (2015)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
por: Steinberg, Benjamin A., et al.
Publicado: (2013)

Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry
por: Fosbol, Emil L., et al.
Publicado: (2013)

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
por: Black‐Maier, Eric, et al.
Publicado: (2017)

Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Holmqvist, Fredrik, et al.
Publicado: (2015)

Heart rate is associated with progression of atrial fibrillation, independent of rhythm
por: Holmqvist, Fredrik, et al.
Publicado: (2015)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
por: Singer, Daniel E., et al.
Publicado: (2015)

Disease understanding in patients newly diagnosed with atrial fibrillation
por: Kaufman, Brystana G, et al.
Publicado: (2018)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
por: Singer, Daniel E., et al.
Publicado: (2013)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation
por: Carlisle, Matthew A., et al.
Publicado: (2022)

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
por: Breithardt, Günter, et al.
Publicado: (2014)

Efficacy of Ablation Lesion Sets in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: Findings From the SMASH‐AF Meta‐Analysis Study Cohort
por: Cluckey, Andrew, et al.
Publicado: (2018)

2135 Impact of primary care physician gatekeeping on medication prescriptions for atrial fibrillation
por: Chang, Andrew Y., et al.
Publicado: (2018)

Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration
por: Din, Natasha, et al.
Publicado: (2023)

AIM‐AF: A Physician Survey in the United States and Europe
por: Camm, A. John, et al.
Publicado: (2022)

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF
por: DeVore, Adam D., et al.
Publicado: (2016)

Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF
por: Ugowe, Francis E., et al.
Publicado: (2021)

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
por: Pol, Tymon, et al.
Publicado: (2021)

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial
por: Carnicelli, Anthony P., et al.
Publicado: (2021)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF
por: Ungar, Leo, et al.
Publicado: (2019)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rmu9jr3fttuo2ciimk9bvd2kbt